A Prospective, Phase II, Neoadjuvant Study Based on Chemotherapy Sensitivity in HR+/HER2- Breast Cancer-FINEST Study

This Phase II, single-arm, prospective study aimed to explore appropriate neoadjuvant treatment strategies for HR+/HER2- breast cancer patients.